fda approve intismeran autogene (v940/mrna-4157)

    Before Oct 1, 2027

    fda approve intismeran autogene (v940/mrna-4157). Best Yes near 62¢ across 1 platform. Live cross-platform prices. Not financial advice.

    Best Yes: 62¢ · Best No: 43¢ · 1 platform

    • Kalshi: Yes 62¢ / No 43¢
    TRADING OPEN

    Before Oct 1, 2027

    Volume

    $551

    $0 24h

    Platforms

    1

    Cross-platform pricing

    Resolution

    Resolves Oct 1, 2027

    ~382 days left

    Category

    Culture

    62¢CHANCE OF YES59%41%
    Yes
    62¢
    Kalshi
    No
    43¢
    Kalshi

    Opens on best-price platform

    Compare & Trade

    1 platform
    kalshi
    Kalshi
    Best Yes
    Best No
    Yes
    62¢
    No
    43¢
    Vol
    $551
    Trade on Kalshi

    Price History

    Loading…

    About This Market

    If the FDA approves intismeran autogene (V940/mRNA-4157) with pembrolizumab (KEYTRUDA) for adjuvant treatment of completely resected stage IIB-IV melanoma for marketing before Oct 1, 2027, then the market resolves to Yes.

    Fee Impact at These Prices

    KalshiKalshiat 62¢: exit costs ~1.65¢/contract
    Full calculator

    Market Details

    ResolutionResolves Oct 1, 2027
    Time Left382 days
    Status● Active
    CategoryCulture

    Sign in to join the discussion

    Sign In